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Abstract
Background: Preoperative capecitabine-based chemoradiation is a standard treatment for locally advanced rectal
cancer (LARC). Here, we explored the safety and efficacy of the addition of bevacizumab to capecitabine and
concurrent radiotherapy for LARC.
Methods: Patients with MRI-confirmed stage II/III rectal cancer received bevacizumab 5 mg/kg i.v. 2 weeks prior to
neoadjuvant chemoradiotherapy followed by bevacizumab 5 mg/kg on Days 1, 15 and 29, capecitabine 825 mg/
m
2 twice daily on Days 1-38, and concurrent radiotherapy 50.4 Gy (1.8 Gy/day, 5 days/week for 5 weeks + three 1.8
Gy/day), starting on Day 1. Total mesorectal excision was scheduled 6-8 weeks after completion of
chemoradiotherapy. Tumour regression grades (TRG) were evaluated on surgical specimens according to Dworak.
The primary endpoint was pathological complete response (pCR).
Results: 61 patients were enrolled (median age 60 years [range 31-80], 64% male). Twelve patients (19.7%) had
T3N0 tumours, 1 patient T2N1, 19 patients (31.1%) T3N1, 2 patients (3.3%) T2N2, 22 patients (36.1%) T3N2 and 5
patients (8.2%) T4N2. Median tumour distance from the anal verge was 6 cm (range 0-11). Grade 3 adverse events
included dermatitis (n = 6, 9.8%), proteinuria (n = 4, 6.5%) and leucocytopenia (n = 3, 4.9%). Radical resection was
achieved in 57 patients (95%), and 42 patients (70%) underwent sphincter-preserving surgery. TRG 4 (pCR) was
recorded in 8 patients (13.3%) and TRG 3 in 9 patients (15.0%). T-, N- and overall downstaging rates were 45.2%,
73.8%, and 73.8%, respectively.
Conclusions: This study demonstrates the feasibility of preoperative chemoradiotherapy with bevacizumab and
capecitabine. The observed adverse events of neoadjuvant treatment are comparable with those previously
reported, but the pCR rate was lower.
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Introduction
Treatment of locally advanced rectal cancer (LARC) is
multimodal and generally consists of surgery, radiation
and chemotherapy. Preoperative radiotherapy (RT) has
been investigated as a neoadjuvant treatment for rectal
cancer to improve local control and survival rates. The
potential advantages of preoperative RT include
decreased tumour spread (local and distant), reduced
acute toxicity, increased sensitivity to RT and enhanced
sphincter preservation during surgery [1-4]. In LARC,
the addition of 5-fluorouracil (5-FU) to preoperative RT
has been shown to improve pathological complete
response rate, tumour downstaging [5] and locoregional
control [6,7] compared with RT alone. Furthermore,
preoperative chemoradiotherapy improves locoregional
control with less toxicity compared with postoperative
chemoradiotherapy [4]. Thus, preoperative chemora-
diotherapy with continuous infusional 5-FU has become
a standard of care in rectal cancer, especially in tumours
of the lower and middle rectum. * Correspondence: vvelenik@onko-i.si
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mimic continuous 5-FU infusion and to generate 5-FU
preferentially in tumour tissue. Capecitabine has demon-
strated efficacy comparable with intravenous 5-FU in
metastatic colorectal cancer as well as in the adjuvant set-
ting in colon cancers [8-14]. Furthermore, capecitabine
has been investigated in various protocols for rectal and
other gastrointestinal cancers in combination with RT
[15]; indeed, equivalence of capecitabine plus RT and 5-
FU plus RT as preoperative therapy in LARC was demon-
strated in the systematic review by Saif and colleagues
[16]. Recently, two phase III trials, the large National Sur-
gical Adjuvant Breast and Bowel Project (NSABP) R-04
Intergroup study [17] and a German trial [18], have con-
firmed that capecitabine is non-inferior to 5-FU as compo-
nent of neoadjuvant radiochemotherapy in rectal cancer,
and a retrospective analysis from a single centre found
preoperative capecitabine plus RT to have more favourable
results and higher downstaging rates that infusional 5-FU
plus RT [19]. Preoperative capecitabine-based chemoradia-
tion is now a standard treatment for LARC [4].
Phase II studies evaluating preoperative doublet che-
motherapy of oxaliplatin or irinotecan plus 5-FU or cape-
citabine combined with concurrent radiotherapy in
LARC have reported either no change or an increase in
pathological complete response with the addition of oxa-
liplatin or irinotecan, and this addition also frequently
resulted in increased acute toxicity [17,18,20-26].
The addition of bevacizumab, a humanized monoclo-
nal antibody to vascular endothelial growth factor
(VEGF), to chemotherapy has been shown to increase
the efficacy of therapy in metastatic colorectal cancer
[ 2 7 ] .I ti sp o s t u l a t e dt h a tc o m b i n i n gb e v a c i z u m a bw i t h
chemoradiation may increase antitumour efficacy by
maximizing inhibition of the VEGF pathway [28,29].
That said, there are relatively limited data on the safety
and efficacy of bevacizumab in combination with che-
motherapy and radiation in the neoadjuvant setting
[30-34]. In this study we explored the safety and efficacy
of neoadjuvant capecitabine, concurrent radiotherapy
and bevacizumab (CRAB) in LARC.
Patients and Methods
We undertook a prospective, open-label, single-arm
phase II study in patients with histologically proven ade-
nocarcinoma of the rectum (Clinicaltrials.gov registration
number: NCT00842686). The study was approved by the
relevant institutional review board, the National Ethics
Committee and the Ministry of Health. All patients gave
written informed consent prior to any study procedure.
Patients
Patient pretreatment work-up comprised a complete
history, physical examination, full blood count, serum
biochemistry, carcinoembryonic antigen, chest radiogra-
phy, ultrasonography and/or computed tomography
(CT) scan of the whole abdomen. The extent of locore-
gional disease was determined by magnetic resonance
imaging (MRI) of the pelvis of each patient. Eligible
patients had to have a histologically verified stage II or
III adenocarcinoma of the rectum, the disease had be
considered either resectable at the time of entry or
thought likely to become resectable after preoperative
chemoradiation with no evidence of distant metastases.
Other key inclusion criteria were: age 18-80 years;
World Health Organization performance status of 0-2;
adequate bone marrow, liver, renal and cardiac function
(no history of clinically significant cardiovascular dis-
ease); no prior radiotherapy, chemotherapy or any tar-
geting therapy for rectal cancer; ability to swallow oral
medications; and signed informed consent. Key exclu-
sion criteria included: other co-existing malignancy or
malignancy within the last 5 years prior the enrolment
other than non-melanoma skin cancer or in situ carci-
noma of the cervix; patients with severe concurrent
medical or psychiatric illness; a known hypersensitivity
to study drug; and pregnant or lactating patients.
Study design and treatment
The study design and treatment schedule are shown in
Figure 1. Three-dimensional CT-based treatment plan-
ning was performed. The CT was taken on treatment
position with 5 mm thick slices. The clinical target
volume was defined as covering the small pelvis from
the L5-S1 interspace to 5 cm below the primary tumour.
The lateral borders were 5 mm outside the true bony
pelvis. The posterior margin covered the sacrum and
the anterior margin encompassed the posterior one-
third to one-half of the bladder and/or vagina. An addi-
tional 1 cm in all directions was added to the clinical
target volume to obtain the planning target volume. The
dose was prescribed to cover the planning target volume
with a 95% reference isodose (95% of the International
Commission on Radiation Unit point dose).
RT was initiated on Day 1. Patients received a total
irradiation dose of 45 Gy to the pelvis plus 5.4 Gy as a
boost to the primary tumour in 1.8 Gy daily fractions
over 5.5 weeks. Radiotherapy was delivered using 15
MV photon beams and four-field box technique, once
daily, 5 days per week. All fields were treated daily. Mul-
tileaf collimators were used to shape individual radiation
fields and for the protection of normal tissues. Patients
were irradiated in a prone position with a full bladder
and using a belly board to minimize exposure of the
small bowel.
Chemotherapy was administered concomitantly with
RT and consisted of oral capecitabine at a daily dose of
1650 mg/m
2, divided into two equal doses given 12
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The chemotherapy started on the first day of RT (Day
1), finished on the last day of RT (Day 38) and was con-
tinuous throughout the RT period (i.e. it included week-
ends). Bevacizumab was administered at a dose of 5 mg/
kg on treatment days: -14, 1, 15 and 29. The drug was
delivered as an intravenous infusion over a 30-90-min
period.
Resection was performed 6-8 weeks after the comple-
tion of chemoradiotherapy. A total mesorectal excision
was the recommended operation for mid and distal rec-
tal tumours. Surgical management included a sphincter-
preservation approach whenever possible. The option
for a temporary colostomy during surgery was left to
the surgeon’s discretion. Complications after surgery
were recorded.
In patients achieving histopathological R0 or R1 resec-
tion, adjuvant chemotherapy was recommended: this
comprised capecitabine 1250 mg/m
2 orally twice daily
on Days 1-14 every 3 weeks; 4 (R0 resection) or 6 cycles
(R1 resection) were recommended, beginning 6-8 weeks
after surgery.
Study assessments
It has been shown that complete eradication of the pri-
mary tumour observed in the histopathological speci-
men (pathological complete response [pCR]) correlates
w i t haf a v o u r a b l eo v e r a l lp r o g n o s i s ,s oo b t a i n i n gap C R
might be beneficial [35]. Thus, the primary endpoint of
pCR rate was selected for the current analysis. Second-
ary endpoints were: pathological response rate (plus
tumour regression grade [TRG] according to Dworak
scale); rate of sphincter-sparing surgical procedure; his-
topathological R0 resection rate; acute and late toxicity
(SOMA/LENT scale); locoregional failure rate; disease-
free survival; and overall survival. The effect of
Day
Eligible for study
Histologically proven stage II/III rectal cancer
-14          -8           1           8          15          22         29         35      38
Surgery 6-8 weeks later
Capecitabine (1250 mg/m2 bd) 4-6 cycles
Capecitabine
(825 mg/m2 bd)
Bevacizumab
(5 mg/kg)
Radiotherapy
(1.8 Gy/day for 5 weeks 
+ boost, total 50.4 Gy)
Figure 1 Study design and treatment schedule.
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was assessed by comparing the pretreatment radiologi-
cally determined TNM stage with the postoperative
pathologic TNM stage. As an exploratory objective, the
mutation status of KRAS in pre-therapeutic biopsies was
established and correlation to pathological response was
assessed.
During treatment, patients were evaluated weekly.
Clinical examinations, complete blood count and serum
chemistry analysis were performed. Adverse events were
assessed according to National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC) version 3.0. Re-eva-
luation of the primary tumour with pelvic MRI was
performed four weeks after the completion of preopera-
tive treatment.
Postoperative, pathological evaluation of the surgical
specimen was performed. pCR was defined as the com-
plete disappearance of all tumour cells. Histological
regression of the primary tumour was semi-quantita-
tively determined according to a 5-point TRG scale:
TRG 0, no regression; TRG 1, minimal regression
(dominant tumour mass with obvious fibrosis and/or
vasculopathy); TRG 2, moderate regression (predomi-
nantly fibrotic changes with few tumour cells or groups);
TRG 3, good regression (very few tumour cells in fibro-
tic tissue); TRG 4, total regression (no tumour cells,
only fibrotic mass).
Follow-up visits were scheduled at 3, 6, 12, 18, 24, 36,
48 and 60 months following the end of adjuvant
chemotherapy.
Statistical analysis
The primary endpoint of the study was pCR rate. In the
medical literature, phase II studies of capecitabine and
RT suggest a pCR rate in the range of 4-31%, while in
our published study the pCR rate was approximately 9%.
We aimed to evaluate whether a 23% pCR rate could be
achieved by adding bevacizumab to standard preopera-
tive treatment. Setting 10% as the lowest pCR rate of
interest, and with alpha error of 5% and power of 80%,
at least 50 evaluable patients were needed (calculated
using power sample calculation, for two samples, per-
centages, a =5 % ,1 - b = 20%). Assuming that ≥10% of
patients would not be evaluable, the estimated sample
size required was at least 60 patients.
Statistics were descriptive and all data were analysed
using the SPSS statistical software package, version 13
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and treatment rates
Between February 2009 and March 2010, a total of 61
patients were recruited. Patients’ baseline and disease
characteristics are summarized in Table 1. Three
patients (4.9%) presented with stage T2 disease, 53
(86.9%) with stage T3, 5 (8.2%) with stage T4; lymph
node involvement was detected in 49 patients (80.3%).
T h em o s tf r e q u e n tM R Is t a g i n gw a su T 3 N +( 6 7 % ) .I n
28 patients (45.9%) the tumour invaded the mesorectal
fascia and in half of the patients (50%) the primary
tumour was sited ≤5 cm from the anal verge.
All patients received neoadjuvant chemoradiotherapy
plus bevacizumab. Treatment was terminated in one
patient as a result of withdrawal of informed consent
following four weeks of treatment. All other patients
received 100% of the expected radiation treatment.
Treatment interruption was necessary for 7 patients
(11.6%) because of grade 2 (n = 2) and grade 3 (n = 3)
leucopenia, grade 3 diarrhoea (n = 1), and grade 3 (n =
1) and grade 4 (n = 1) vascular toxicity. Other grade 3
toxicities included dermatitis (n = 6), proteinuria (n = 4)
and hypertension (n = 1). There were no treatment-
related deaths during the study.
RT was interrupted for 2-7 days as a result of treat-
ment (median interruption: 2 days), while 56 patients
(91%) received 95-100% of the designated chemotherapy
dose. Overall, 58 patients (95.1%) received all four infu-
sions of bevacizumab while the remaining 3 patients
received three infusions.
Table 1 Patients’ baseline and disease characteristics
Characteristics Patients
(n = 61)
Median age, years (range) 60 (31-80)
Gender, n (%):
Male 39 (64)
Female 22 (36)
WHO performance status, n (%)
0 52 (85)
1 9 (15)
TN clinical stage, n (%)
T3N0 12 (19.7)
T2N1 1 (1.7)
T3N1 19 (31.1)
T2N2 2 (3.3)
T3N2 22 (36.1)
T4N2 5 (8.2)
Median clinical tumour size per MRI, cm (range) 6 (1-12)
Median tumour distance from anal verge, cm (range) 6 (0-11)
Type of surgery
a, n (%)
Low anterior resection 35 (57.4)
Coloanal reconstruction 10 (16.4)
Abdominoperineal resection 14 (23.0)
Pelvic exenteration 2 (3.3)
aAs planned before the start of preoperative chemoradiotherapy.
MRI, magnetic nuclear imaging; N, node; T, tumour; WHO, World Health
Organization.
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The frequency and grade of treatment-related acute
toxicities are summarised in Table 2. The most frequent
adverse event reported with chemoradiotherapy was
grade 2 and 3 radiodermatitis. During treatment, 25
patients lost weight; the maximum body weight loss was
6.5% (median 3.3%). Of the remaining patients, 26 main-
tained a constant weight and nine experienced a weight
increase of up to 5% (median: 2.4%).
Surgery rates and outcomes
All patients underwent definitive surgery, although one
patient revealed distant metastases after completion of
chemoradiotherapy. Surgery was performed 25 to 79
days (median: 55 days) after the last day of chemora-
diotherapy. Exploratory surgery was performed in only 1
patient because of a large, unresectable T4 tumour with
peritoneal carcinomatosis. The median hospital stay for
surgery was 11 days (range: 7-32 days).
Radical resection was achieved in 57 patients (95%)
and 42 patients (70%) underwent sphincter-preserving
surgery. A temporary stoma was created in 41 patients.
In one patient pathohistological examination of the sur-
gical specimen revealed malignant melanoma; this
patient was considered misdiagnosed and excluded from
the efficacy analysis.
Pathological TNM stages in relation to preoperative
TNM status are presented in Table 3. TRG 4 (pCR) was
recorded in 8/60 patients (13.3%) and TRG 3 in 9/60
patients (15.0%). T-, N- and overall downstaging rates
were 46.7%, 65.0% and 75.0%, respectively.
KRAS mutations were found in 20 (33.9%) out of 59
bioptic tumour samples obtained before preoperative
treatment. KRAS status was not associated with patholo-
gical response.
In total, 38 patients (62.3%) developed perioperative
complications. The most frequent were delayed wound
healing (n = 18, 30.0%), infection/abscess (n = 12,
20.0%) and anastomotic leakage (n = 7, 11.7%). Six
patients required surgical re-intervention for anastomo-
tic leakage (n = 3), abdominal abscess (n = 2) and pneu-
mothorax (n = 1). There were no perioperative deaths.
A summary of perioperative toxicity is shown in Table
4.
Postoperative chemotherapy was administered to 51
(83.6%) patients. Reasons for not administering adjuvant
chemotherapy were: progression of the disease (n = 2),
misdiagnosis (n = 1); withdrawal from study (n = 1); > 8
week interval between the operation and adjuvant ther-
apy (n = 1); and postoperative complications (n = 5).
Postoperative chemotherapy comprised capecitabine
1250 mg/m
2 on Days 1-14 every 3 weeks for 4 or 6
cycles. A total of 42 patients received all planned cycles.
Two patients only received 3 cycles because of disease
progression (n = 1) and death because of pulmonary
thromboembolism (n = 1); 2 patients only received 2
cycles because of diarrhoea and dehydration (n = 1) and
nonspecific chest pain (n = 1); and 3 patients only
received 1 cycle because of the development of presacral
abscesses (n = 2) and nonspecific chest pain (n = 1).
Discussion
This phase II study demonstrates the feasibility of preo-
perative chemoradiation with bevacizumab and capecita-
bine in patients with LARC. Indeed, a high R0 resection
rate was achieved despite tumour invasion of the mesor-
ectal fascia in 46% of patients. A well-accepted approach
in the management of LARC is neoadjuvant fluoropyri-
midine-based chemoradiation and a number of prospec-
tive and retrospective trials have suggested that
preoperative capecitabine is at least equivalent to infu-
sional 5-fluorouracil when combined with RT [16-19],
and may improve tumour downstaging. In 2009, the US
National Comprehensive Cancer Network recommended
capecitabine as an acceptable alternative to 5-FU in this
setting [36].
The pCR rate of 13% observed with neoadjuvant cape-
citabine plus bevacizumab plus RT was similar to an
earlier phase II study by our group examining neoadju-
vant single-agent capecitabine plus RT in LARC [37].
This pCR rate, albeit relatively low, is within the range
0-31% reported across a number of phase II studies
evaluating single-agent capecitabine plus RT [38-43]. In
Table 2 Acute toxicities occurring during preoperative
chemoradiotherapy
Patients, n (%)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Haematological:
Leucocytopenia 12 (19.7) 5 (8.2) 3 (4.9) -
Anaemia 5 (8.2) - - -
Non-haematological:
Diarrhoea 14 (22.9) 4 (6.5) 1 (1.6) -
Fatigue 7 (11.5) 3 (4.9) - -
Nausea 5 (8.2) - - -
Anorexia 2 (3.3) - - -
Dermatitis 3 (4.9) 14 (22.9) 6 (9.8) -
Hand-food syndrome 5 (8.2) 2 (3.3) - -
Cystitis 3 (4.9) - - -
Hepatotoxicity 2 (3.3) 2 (3.3) - -
Vascular - - 1 (1.6) 1 (1.6)
Proteinuria 10 (16.4) 2 (3.3) 4 (6.5) -
Hypertension 2 (3.3) 2 (3.3) 1 (1.6) -
Infection 3 (4.9) 5 (8.2) - -
Pain 20 (32.8) 3 (4.9) - -
Bleeding 10 (16.4) - - -
According to National Cancer Institute Common Toxicity Criteria (version 3)
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rate was 12% [44], and in the recently presented
NSABP-04 study the pCR ranged from 18 to 22% with
capecitabine and 5-FU achieving similar rates of
improvement but no additional benefit being observed
with the addition of oxaliplatin to either of these agents
[17]. A study by Ofner and co-workers [45] evaluating
preoperative capecitabine and oxaliplatin reported a
pCR rate of 10% while studies investigating preoperative
capecitabine, oxaliplatin and bevacizumab found rates of
24-36% [32-34].
In the phase II trial by Crane and coworkers [31], 25
patients with LARC received neoadjuvant chemora-
diotherapy with bevacizumab (three doses of 5 mg/kg
given every 2 weeks) and capecitabine (900 mg/m
2 orally
twice daily on days of radiation therapy), followed by
surgical resection a median of 7.3 weeks later. These
authors reported a pCR rate of 32% (8 patients), which
is considerably higher than that reported here. One pos-
sible explanation for the relatively low pCR rate
observed in our study was that the patients in this study
had advanced tumours; indeed, most of the patients had
regionally advanced disease and in almost half of the
patients the tumour had invaded the mesorectal fascia.
However, caution is needed when comparing pCR rates
as the pCR rate itself is highly dependent on the quality
of the pathological examination [46] and a longer inter-
val between end of chemoradiotherapy and surgery (6-8
weeks vs. 2 weeks) has been reported to increase pCR
rate without reducing local recurrence rate or survival
[47,48]. While there has been much debate about
whether pCR is associated with a favourable long-term
outcome, a recently published pooled analysis of data
from 3105 patients from 14 studies would suggest that
patients with pCR after chemoradiation have better
long-term outcome than those without pCR [49].
The adverse event profile observed during neoadjuvant
capecitabine plus bevacizumab chemoradiotherapy was
comparable with those reported in an earlier study
involving capecitabine plus bevacizumab with concur-
rent RT [31]. The most frequent preoperative adverse
events were dermatitis, pain and leucopenia, and adverse
events related to bevacizumab therapy were relatively
infrequent. Any postoperative adverse events were
mainly related to delayed wound healing and infection/
abscess. No treatment-related deaths were recorded.
These results, together with those of Crane and co-
workers [31] suggest that the combination of neoadju-
vant capecitabine plus bevacizumab with concurrent RT
is feasible and well tolerated in the treatment of LARC.
A high radical resection rate suggests its potential posi-
tive effect on tumour downstaging. The observed
adverse events during neoadjuvant treatment in our
study are comparable with those reported previously;
however, no clinically relevant increase in pathologic
response rate was observed. Longer follow-up is needed
to assess the impact on other efficacy endpoints.
Long-term follow-up data on survival and local con-
trol in patients with LARC having undergone neoadju-
vant capecitabine plus bevacizumab chemoradiotherapy
followed by surgery are eagerly awaited. It will also be
interesting to compare any long-term follow-up data
with that which is currently available at the moment on
single-agent capecitabine-based chemoradiotherapy
[39,50] to help determine the benefits of adding bevaci-
zumab to the regimen.
Conclusion
The results of this phase II study indicate that neoadju-
vant capecitabine chemoradiotherapy is an effective
treatment for patients with LARC and the incorporation
of bevacizumab into a standard capecitabine-based che-
moradiotherapy regimen is feasible and well tolerated.
Table 3 Distribution of postoperative pathological TMN stages compared with pretreatment clinical stages (n = 60)
Before After surgery (pTNM)
T0N0 T1N0 T2N0 T3N0 T2N1 T3N1 T4N1 T3N2
T3N0 34 32
T2N1 1
T3N1 53 4 41 1
T2N2 1 1
T3N2 1 2 13 1 1 4
T4N2 12 1 1
Total 8 (13.3%) 5 (8.3%) 14 (23.3%) 21 (35%) 1 (1.7%) 5 (8.3%) 1 (1.7%) 5 (8.3%)
c - Clinical, p - pathological, T - Tumour, N - Node, M - Metastasis.
Table 4 Perioperative adverse events (n = 60)
Complication Patients, n (%)
a
Delayed healing of postoperative wound 18 (30.0)
Infection/abscess 12 (20.0)
Pneumothorax 1 (1.7)
Anastomotic leakage 7 (11.7)
aPatients could have more than one adverse event.
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